Episode 21 – Allogeneic cell therapies and the immune system
This episode defines allogeneic cell therapy as the administration of cells to a patient for therapeutic use, that were not initially taken from that patient.
This episode is the second part of our series: Cell Talk: A Comprehensive Guide to Next-Gen Cell Therapy. We are defining allogeneic cell therapy as the administration of cells to a patient for therapeutic use, that were not initially taken from that patient.
This conversation features Andy Holt, CCO at Cellistic, and Dr Tracey Lodie, CSO at Quell Therapeutics.
Key learning points:
- Specific roles of different immune cells in combating diseases
- Autologous vs allogeneic therapies
- Cell therapies for cancer treatment and diseases
Andy brings more than fifteen years of experience in cell and gene therapy to Cellistic. In his prior roles, he held business development, corporate development and management positions for CDMOs, driving commercial strategy and growth in adeno-associated virus (AAV) gene therapy manufacturing.
In his role at Cellistic, Andy leverages his experience in scaling up cell and gene therapy platforms to help Cellistic clients reach their goals in allogeneic cell therapy.
Dr Tracey Lodie
Dr Tracey Lodie Lodie joined Quell in July 2021 bringing more than 20 years of experience in the biopharmaceutical industry focused on the discovery and development of cell therapies and novel biologics in the areas of autoimmunity, transplant biology and immune-oncology. She joins from Gamida Cell, a clinical-stage, Nasdaq-listed cell therapy company, where she served as CSO with responsibility for strategic oversight of its cell therapy pipeline and overseeing translational research for clinical programs.
Prior to this, Dr Lodie served as SVP, translational immunology at BlueRock Therapeutics, where she helped to advance its universal pluripotent stem cell (PSC) platform into multiple therapeutic areas; and as VP of immunology at Syros Pharmaceuticals, where she developed new autoimmunity and immuno-oncology research programs. She also spent 15 years at Sanofi-Genzyme and was instrumental in advancing several development programs through regulatory approval in the areas of transplant and autoimmunity.
Dr. Lodie completed postdoctoral work in hematology/oncology at Harvard Medical School. She holds a Ph.D. in immunology and pathology from Boston University School of Medicine and a B.S. in biology from Fairfield University